International comparative study on high-value drugs payment system and its implications for China / 中国卫生政策研究
Chinese Journal of Health Policy
;
(12): 44-49, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-508353
ABSTRACT
Objective:
The aim of the present study was to conduct an international comparison of the high-val-ue drugs payment systems of some selected countries, and introduce them to the Chinese context. Australia, America and Germany's high-value drugs payment systems were selected to serve as references for China.Methods:
The main content and characteristics of three countries' payment systems were analyzed in four aspectsexpenditure copayment mode, paid-scope selection, drug price negotiation, and drug rational use management which were then compared with the Chinese status.Results:
Through the difference in healthcare system tradition, the above countries have vari-ous copayment mode, but they all select paid-drug by cost-effectiveness analysis with corresponding control measures.Conclusions:
China should establish a co-payment mode for the high-value drugs on the basis of a critical illness medical insurance found;build a national pharmaco-economic evaluation index system and improve the national nego-tiation superiority, while emphasizing on risk-sharing mechanism; and make series specifications to guarantee the drug to be rationally used.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Health Policy
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS